Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

MN-166 trial clears DSMB review
February 2017
SHARING OPTIONS:

LA JOLLA, Calif.—MediciNova Inc. recently reported that based on the Data and Safety Monitoring Board (DSMB) review of the interim efficacy analysis, its ongoing Phase 2b clinical trial of MN-166 in progressive multiple sclerosis will continue, per the DSMB’s recommendation to the NIH’s National Institute of Neurological Diseases and Stroke. The trial is investigating the safety, tolerability and efficacy of MN-166 when administered twice daily to patients with primary progressive or secondary progressive multiple sclerosis. The primary objectives are to evaluate MN-166’s activity vs. placebo at 96 weeks and to evaluate its safety and tolerability vs. placebo.
 
“We are very pleased that this important study will continue as planned and we believe this is an encouraging sign. The unmet medical need for progressive MS patients is extremely high as there is no treatment approved for long-term use for these patients,” said Dr. Robert Fox of the Cleveland Clinic, principal investigator of the trial.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.